Back to top
more

Ocuphire Pharma (OCUP)

(Real Time Quote from BATS)

$1.60 USD

1.60
44,500

+0.07 (4.24%)

Updated Apr 26, 2024 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for OCUP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Ocuphire Pharma, Inc. [OCUP]

Reports for Purchase

Showing records 1 - 20 ( 21 total )

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/11/2024

Company Report

Pages: 7

Focusing Sights on Oral APX3330 Phase 3 Advancement in NPDR; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 25.00

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/14/2023

Company Report

Pages: 7

Oral APX3330 Advancement in DR, With Partnered Nyxol Approval in RM; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/10/2023

Industry Report

Pages: 8

Boots on the Ground at AAO’23-KOL Perspectives and Considerations on Therapeutic Ophthalmic Innovations

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

09/27/2023

Daily Note

Pages: 3

FDA Approval of Ryzumvi in RM Sets Stage For Partnered Nyxol Platform; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/14/2023

Company Report

Pages: 7

2023 As Year of Platform Catalysts Across Both APX3330 and Nyxol; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

05/16/2023

Company Report

Pages: 7

Nyxol PDUFA Approaches While Determining APX3330 Path Forward; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

03/31/2023

Company Report

Pages: 7

Broad Nyxol Refractive Platform Advancement to Define 2023; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

02/17/2023

Daily Note

Pages: 4

Focusing Broadly on Nyxol, With APX3330 Further Pipeline Upside; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

01/26/2023

Company Report

Pages: 7

ZETA-1 Primary Endpoint Miss to Determine APX3330 Path; Adjustments With Announced Partnership; PT Down to $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

11/08/2022

Daily Note

Pages: 5

Nyxol Global License Agreement Paves Refractive Path Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

11/07/2022

Company Report

Pages: 7

Platform Firing on All Cylinders-ZETA-1 Data and Nyxol NDA in Near Term; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

10/17/2022

Daily Note

Pages: 4

APX3330-KOL Perspectives on Oral Therapy in DR/DME, Top-Line Expected 4Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/15/2022

Company Report

Pages: 7

Planned Nyxol NDA in RM, Broader Pipeline Catalysts to Define 2022; Reit. Buy and $26 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/20/2022

Daily Note

Pages: 4

Phase 3 LYNX-1 Trial Delivers Diversification for Refractive Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/16/2022

Company Report

Pages: 7

Nyxol Catalysts Set Stage for 2022; APX3330 Top-Line Expected 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

04/29/2022

Daily Note

Pages: 4

MIRA Program Success Paves Way to Anticipated Late 2022 NDA Submission in RM

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

03/30/2022

Daily Note

Pages: 4

Phase 3 MIRA-3 Clarity in RM Asserts Nyxol Impact for Pupil Modulation

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

03/25/2022

Company Report

Pages: 7

Upcoming 2022 Catalysts-Opportunity to Lead Year With Reversal of Mydriasis

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

02/01/2022

Daily Note

Pages: 4

Catalyst-Rich 2022 Complemented by KOL Engagement; RM Top Line Expected Early ‘22

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Ocuphire Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

11/24/2021

Company Report

Pages: 60

Pupil Modulatory Platform Sets Sights on Nyxol; Initiating With Buy Rating and $26 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 50.00

Research Provided by a Third Party